Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
BCYC Quote, Financials, Valuation and Earnings
Last price:
$5.55
Seasonality move
:
-9.89%
Day range:
$5.23 - $5.57
52-week range:
$5.03 - $12.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.54x
P/B ratio:
0.86x
Volume:
127.1K
Avg. volume:
340.9K
1-year change:
-54.85%
Market cap:
$384.3M
Revenue:
$35.3M
EPS (TTM):
-$3.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.95 | -21.41% | -6.65% | $18.80 |
|
AUTL
Autolus Therapeutics Plc
|
$23.9M | -$0.43 | 205.06% | -3.26% | $8.99 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
DBVT
DBV Technologies SA
|
$1.3M | -$0.22 | -- | -86.12% | $40.16 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $3.45 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
$5.54 | $18.80 | $384.3M | -- | $0.00 | 0% | 13.54x |
|
AUTL
Autolus Therapeutics Plc
|
$1.64 | $8.99 | $436.5M | -- | $0.00 | 0% | 8.52x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.29 | $17.94 | $1.1M | -- | $0.00 | 0% | 0.73x |
|
DBVT
DBV Technologies SA
|
$21.07 | $40.16 | $1.2B | -- | $0.00 | 0% | -- |
|
MREO
Mereo BioPharma Group Plc
|
$0.43 | $3.45 | $68.7M | -- | $0.00 | 0% | 134.89x |
|
NCNA
NuCana Plc
|
$2.15 | $104.00 | $8.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.520 | 1.21% | 9.36x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.023 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.992 | 5.85% | 1.41x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.707 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.482 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Bicycle Therapeutics Plc vs. Competitors
-
Which has Higher Returns BCYC or AUTL?
Autolus Therapeutics Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of -373.3%. Bicycle Therapeutics Plc's return on equity of -34.37% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About BCYC or AUTL?
Bicycle Therapeutics Plc has a consensus price target of $18.80, signalling upside risk potential of 239.35%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $8.99 which suggests that it could grow by 448.17%. Given that Autolus Therapeutics Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Autolus Therapeutics Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 AUTLAutolus Therapeutics Plc10 0 0 -
Is BCYC or AUTL More Risky?
Bicycle Therapeutics Plc has a beta of 1.630, which suggesting that the stock is 63.002% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.946%.
-
Which is a Better Dividend Stock BCYC or AUTL?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or AUTL?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Bicycle Therapeutics Plc's net income of -$58.7M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 13.54x versus 8.52x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc13.54x -- $11.7M -$58.7M AUTLAutolus Therapeutics Plc8.52x -- $21.1M -$78.6M
-
Which has Higher Returns BCYC or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of --. Bicycle Therapeutics Plc's return on equity of -34.37% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About BCYC or BDRX?
Bicycle Therapeutics Plc has a consensus price target of $18.80, signalling upside risk potential of 239.35%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 13686.92%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is BCYC or BDRX More Risky?
Bicycle Therapeutics Plc has a beta of 1.630, which suggesting that the stock is 63.002% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock BCYC or BDRX?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or BDRX?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 13.54x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc13.54x -- $11.7M -$58.7M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns BCYC or DBVT?
DBV Technologies SA has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of --. Bicycle Therapeutics Plc's return on equity of -34.37% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About BCYC or DBVT?
Bicycle Therapeutics Plc has a consensus price target of $18.80, signalling upside risk potential of 239.35%. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 90.6%. Given that Bicycle Therapeutics Plc has higher upside potential than DBV Technologies SA, analysts believe Bicycle Therapeutics Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 DBVTDBV Technologies SA4 0 1 -
Is BCYC or DBVT More Risky?
Bicycle Therapeutics Plc has a beta of 1.630, which suggesting that the stock is 63.002% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.
-
Which is a Better Dividend Stock BCYC or DBVT?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or DBVT?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than DBV Technologies SA quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is lower than DBV Technologies SA's net income of -$33M. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 13.54x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc13.54x -- $11.7M -$58.7M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns BCYC or MREO?
Mereo BioPharma Group Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of -2923.31%. Bicycle Therapeutics Plc's return on equity of -34.37% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About BCYC or MREO?
Bicycle Therapeutics Plc has a consensus price target of $18.80, signalling upside risk potential of 239.35%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.45 which suggests that it could grow by 511.54%. Given that Mereo BioPharma Group Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Mereo BioPharma Group Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 MREOMereo BioPharma Group Plc4 1 0 -
Is BCYC or MREO More Risky?
Bicycle Therapeutics Plc has a beta of 1.630, which suggesting that the stock is 63.002% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.310, suggesting its less volatile than the S&P 500 by 68.983%.
-
Which is a Better Dividend Stock BCYC or MREO?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or MREO?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 13.54x versus 134.89x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc13.54x -- $11.7M -$58.7M MREOMereo BioPharma Group Plc134.89x -- -- -$7M
-
Which has Higher Returns BCYC or NCNA?
NuCana Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of --. Bicycle Therapeutics Plc's return on equity of -34.37% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics Plc has a consensus price target of $18.80, signalling upside risk potential of 239.35%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 969596.97%. Given that NuCana Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe NuCana Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 NCNANuCana Plc0 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics Plc has a beta of 1.630, which suggesting that the stock is 63.002% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.66%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than NuCana Plc quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is lower than NuCana Plc's net income of -$378.9K. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 13.54x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc13.54x -- $11.7M -$58.7M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 1.34% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 1.16% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.29% over the past day.
